Abstract:Abstract Background Numerous laboratory and clinical studies have evidenced that MAO‐B inhibitors are a potential therapeutic approach for the treatment of AD. Thus, drugs used to inhibit activated MAO, including rasagiline, ladostigil and selegiline, may provide neuroprotection against AD by improving cognitive impairment, modulating the proteolytic cleavage of APP and decreasing levels of Aβ protein fragments that accumulate in the brain. Future clinical studies on MAO inhibitors for the treatment of AD may provide further insights into the mechanism of action of antioxidants as therapeutic agents for AD. Method Series of donepezil‐indolyl hybrids were prepared and characterized via highresolution mass spectrometry, 1 H nuclear magnetic resonance and 13 C nuclear magnetic resonance techniques. In vitro fluorometric assay (by Amplex® UltraRed reagent to detect hydrogen peroxide or peroxidase activity in biological samples or enzymes.) was used to investigate the activity of the synthesized compounds on both MAO‐A and MAO‐B isozymes as well as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) by Ellman method with modifications. Result The biological evaluation of molecules 1‐30 showed that most of these compounds are potent, in the nanomolar range, and selective AChEI, with moderate and equipotent selectivity for MAO‐A and MAO‐B inhibition. In overall, compound 11, as a potent and selective dual AChEI, showing a moderate MAO inhibitory profile, can be considered as an attractive multipotent drug for further development on two key pharmacological targets playing key roles in the therapy of Alzheimer’s disease. Conclusion The pharmacological profile of compound 11, as well as the fact that it is a readily available compound in a short synthetic sequence, in good chemical yields, prompts us to select it as a lead‐compound for further optimization in our current research programme targeted to the preparation of new molecules for the potential treatment of AD.

Design, Synthesis and Evaluation of Novel Dual Monoamine-Cholinesterase Inhibitors As Potential Treatment for Alzheimer’s Disease

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

A Novel Neuroprotective Cholinesterase-Monoamine Oxidase Inhibitor for Treatment of Dementia and Depression in Parkinson’s Disease

Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential anti-Alzheimer's Disease Agents.

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Design, Synthesis, and Bioevaluation of Indole Core Containing 2-Arylidine Derivatives of Thiazolopyrimidine As Multitarget Inhibitors of Cholinesterases and Monoamine Oxidase A/B for the Treatment of Alzheimer Disease

Design, Synthesis and Biological Evaluation of New 3,4-Dihydro-2(1<i>H</i>)-Quinolinone-Dithiocarbamate Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Unleashing new MTDL AChE and BuChE inhibitors as potential anti-AD therapeutic agents: In vitro , in vivo and in silico studies

Design, Synthesis and Biological Evaluation of Dual Acetyl Cholinesterase and Beta-Secretase Inhibitors in Treatment for Alzheimer's Disease.

Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (ache) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease

Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.

Novel Donepezil-Chalcone-rivastigmine Hybrids As Potential Multifunctional Anti-Alzheimer's Agents: Design, Synthesis, in Vitro Biological Evaluation, in Vivo and in Silico Studies.

Novel Dual Inhibitors Targeting Acetylcholinesterase and Monoamine Oxidases for Alzheimer's Therapy

Novel AP2238-clorgiline hybrids as multi-target agents for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation

Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives.

Synthesis and evaluation of 6-substituted 3-arylcoumarin derivatives as multifunctional acetylcholinesterase/monoamine oxidase B dual inhibitors for the treatment of Alzheimer’s disease

Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors Based on the Pyridyl–Pyridazine Moiety for the Potential Treatment of Alzheimer's Disease

Donepezil‐indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer’s disease

Design, Synthesis and Biological Evaluation of 1-Phenyl-ethanone Derivatives for Multi-Targeted Treatment of Alzheimer's Disease

Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer’s disease

Multi-targeted ChEI-copper Chelating Molecules As Neuroprotective Agents.